The Scotts Miracle-Gro Company
SMG
$59.00
-2.45%
The Scotts Miracle-Gro Company is the largest purveyor of home lawn and gardening products in the United States, operating within the Agricultural Inputs industry. The company is a dominant market leader with a portfolio of well-recognized consumer brands including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat. The current investor narrative is centered on a strategic refocus and potential turnaround, highlighted by the recent divestiture of The Hawthorne Gardening Company, which signals management's intent to streamline operations and concentrate on the core consumer lawn and garden business amidst ongoing challenges in revenue and profitability.…
SMG
The Scotts Miracle-Gro Company
$59.00
Related headlines
Investment Opinion: Should I buy SMG Today?
Rating: Hold. The core thesis is that SMG is a highly speculative turnaround story with severe balance sheet risks offset by a dominant market position and deep-value valuation, making it unsuitable for most investors but potentially interesting for high-risk capital seeking asymmetric upside.
Supporting evidence includes a trailing PS ratio of 0.96, which is near historical lows and suggests limited further multiple compression. The company generated strong TTM free cash flow of $358.1M, providing a crucial lifeline. However, this is overshadowed by a -35.3% net margin in the latest quarter and a critically negative ROE of -40.6%. The stock's 1-year price change of -3.14% and severe underperformance versus the market further highlight its challenged state.
The thesis would upgrade to a speculative Buy if the company demonstrates sustained quarterly gross margin recovery above 30%, shows a clear path to reducing absolute debt levels, and the stock holds firmly above its 52-week low on heavy volume. It would downgrade to a Sell if Q2 or Q3 2026 earnings disappoint, indicating the core seasonal profitability is broken, or if liquidity metrics like the current ratio deteriorate significantly. Based on the current data, the stock appears fairly valued for its high-risk profile—it is not overvalued given its problems, nor is it clearly undervalued given the magnitude of those problems.
Sign up to view all
SMG 12-Month Price Forecast
The outlook for SMG is bifurcated between its operational potential and financial peril. The base case of a volatile, sideways grind is most probable, as the company's strong brand and cash flow generation battle against an unsustainable capital structure. The recent divestiture is a positive step but not a guaranteed solution. The stance would upgrade to bullish only upon clear evidence of debt reduction and sustained margin recovery in the upcoming peak season earnings. It would turn bearish if the next quarterly report shows further erosion in the core business's profitability, threatening the vital free cash flow.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Scotts Miracle-Gro Company's 12-month outlook, with a consensus price target around $76.70 and implied upside of +30.0% versus the current price.
Average Target
$76.70
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$47 - $77
Analyst target range
Analyst coverage is minimal, with only 3 analysts providing estimates, indicating limited institutional interest which can lead to higher volatility and less efficient price discovery. The data provides consensus EPS and revenue estimates but does not include a consensus recommendation, average price target, or target range. Therefore, it is impossible to calculate implied upside/downside or gauge the bullish/bearish sentiment spread. The implication of such sparse coverage is that the stock is likely not a priority for major sell-side firms, possibly due to its mid-cap size, cyclical nature, and recent financial challenges. Investors must rely more heavily on their own fundamental and technical analysis rather than consensus views, acknowledging the increased uncertainty and potential for mispricing that comes with limited analyst scrutiny.
Bulls vs Bears: SMG Investment Factors
The bear case currently holds stronger evidence, anchored by the company's deteriorating financial fundamentals, extreme leverage, and persistent stock price decline. The bull case rests on a deep-value valuation and the potential for a successful strategic turnaround. The single most important tension in the investment debate is whether management's refocus on the core business can stabilize profitability and generate sufficient cash flow to service its massive debt burden before the weak balance sheet triggers a more severe crisis. The resolution of this leverage versus operational turnaround dynamic will determine the stock's fate.
Bullish
- Deep Value Price-to-Sales Ratio: The stock trades at a trailing PS ratio of 0.96, near the bottom of its historical range from a high of 15.76. This suggests the market has priced in significant pessimism, offering a potential margin of safety if the company's strategic refocus succeeds.
- Strong Free Cash Flow Generation: Despite quarterly losses, the company generated $358.1 million in trailing twelve-month free cash flow. This robust cash generation provides financial flexibility to manage debt and fund operations during its turnaround.
- Strategic Refocus via Divestiture: The recent sale of The Hawthorne Gardening Company signals management's intent to streamline and concentrate on the profitable core U.S. Consumer business. This could improve capital allocation and operational focus.
- Healthy Short-Term Liquidity: A current ratio of 1.27 indicates the company can comfortably meet its short-term obligations. This reduces near-term solvency risk despite the highly leveraged balance sheet.
Bearish
- Severe Financial Leverage & Negative Equity: The balance sheet is critically strained with a debt-to-equity ratio of -6.66 and a negative ROE of -40.6%. This indicates shareholder equity is depleted, amplifying financial risk and limiting strategic options.
- Deepening Cyclical Losses: Q1 2026 revenue declined 15% YoY to $354.4M, with the net loss widening to -$125M (net margin -35.3%) from -$69.5M a year prior. This shows accelerating deterioration in the off-season, a core vulnerability.
- Persistent Technical Downtrend: The stock is down 15.86% over 3 months and 5.48% over the past month, severely underperforming the S&P 500. Trading 18% below its 52-week high confirms sustained selling pressure with no clear bottom.
- High Volatility & Market Correlation: A beta of 1.862 means the stock is 86% more volatile than the market. This magnifies downside risk during market downturns and increases portfolio risk for conservative investors.
SMG Technical Analysis
The stock is in a sustained downtrend, evidenced by a 1-year price change of -3.14% and a more severe 3-month decline of -15.86%. Currently trading at $59, the price sits approximately 35% above its 52-week low of $52 but 18% below its 52-week high of $72.35, positioning it in the lower-middle of its annual range and suggesting it has not yet found a durable bottom. Recent momentum is decisively negative, with the stock down 5.48% over the past month, sharply underperforming the S&P 500 which gained 6.31% over the same period, resulting in a stark relative strength reading of -11.79. This short-term weakness confirms and accelerates the longer-term downtrend, indicating persistent selling pressure. Key technical support is the 52-week low area around $52, while resistance is the recent high area near $72.35. A breakdown below $52 would signal a new leg down, whereas a sustained move above $72.35 would be needed to suggest a trend reversal. The stock's beta of 1.862 indicates it is approximately 86% more volatile than the broader market, which amplifies both downside risk and potential upside during recoveries, a critical factor for risk-aware investors.
Beta
1.86
1.86x market volatility
Max Drawdown
-25.3%
Largest decline past year
52-Week Range
$52-$72
Price range past year
Annual Return
-3.1%
Cumulative gain past year
| Period | SMG Return | S&P 500 |
|---|---|---|
| 1m | -5.5% | +5.0% |
| 3m | -15.9% | +10.2% |
| 6m | +4.2% | +11.0% |
| 1y | -3.1% | +28.4% |
| ytd | -0.7% | +10.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SMG Fundamental Analysis
Revenue is exhibiting significant volatility and recent weakness, with Q1 2026 revenue of $354.4 million representing a 15% year-over-year decline. The multi-quarter trend shows extreme seasonality, with strong profitability in Q2 and Q3 (e.g., Q2 2025 revenue of $1.42 billion and net income of $217.5 million) but deep losses in the off-season Q1 and Q4, indicating the business is highly cyclical. The U.S. Consumer Segment, which generated $328.5 million in the latest quarter, remains the core driver, though overall growth is challenged. Profitability is deeply negative in the reported quarter, with a net loss of $125 million and a gross margin of 25.0%, which is compressed from the 30.6% trailing gross margin. The company oscillates between high profitability in peak seasons and substantial losses in others, with the latest Q1 net margin of -35.3% showing deterioration from the -16.7% net margin in Q1 of the prior year. The balance sheet shows significant financial strain, with a negative debt-to-equity ratio of -6.66 and a negative Return on Equity of -40.6%, indicating shareholder equity is depleted. However, trailing twelve-month free cash flow is a positive $358.1 million, and the current ratio is a healthy 1.27, suggesting the company can meet short-term obligations, but the leveraged capital structure poses a long-term risk.
Quarterly Revenue
$354400000.0B
2025-12
Revenue YoY Growth
-0.14%
YoY Comparison
Gross Margin
+0.25%
Latest Quarter
Free Cash Flow
$358099999.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SMG Overvalued?
Given the company's negative net income in the most recent quarter, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 0.96, while the Enterprise Value-to-Sales (EV/Sales) is 1.78. The absence of a forward PS ratio in the data limits a direct growth expectation comparison, but the modest sales multiple suggests the market is not pricing in aggressive top-line expansion. Compared to industry averages, specific sector multiples are not provided in the data, making a peer comparison unavailable. However, a PS ratio below 1.0 typically indicates the market has low expectations for growth or profitability. Historically, the stock's own PS ratio has fluctuated wildly, from a high of 15.76 in early 2022 down to the current 0.96. The current PS of 0.96 is near the very bottom of its observable historical range, which could signal a deep value opportunity if fundamentals stabilize, but more likely reflects the market's severe discount for the company's cyclical losses, high financial leverage, and ongoing strategic uncertainty.
PE
22.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -45x~20x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on the company's unsustainable capital structure and volatile earnings. The negative debt-to-equity ratio of -6.66 indicates equity is underwater, meaning the company is technically insolvent on a book value basis. This extreme leverage, coupled with a negative ROE of -40.6%, creates a high risk of financial distress if interest rates remain elevated or operating cash flow weakens. Furthermore, the business exhibits extreme seasonality, swinging from a Q2 2025 net income of $217.5M to a Q1 2026 net loss of -$125M. This earnings volatility makes consistent debt service challenging and complicates forecasting.
Market & Competitive Risks include valuation compression and high sensitivity to broader market moves. Trading at a PS ratio of 0.96, the stock is not expensive, but its high beta of 1.862 means it is likely to fall disproportionately during market corrections. The stock's 25.26% max drawdown and -31.35% 1-year relative strength versus the S&P 500 demonstrate this vulnerability. Competitively, the company's core lawn and garden market is mature and potentially sensitive to consumer discretionary spending cuts, regulatory scrutiny on pesticides, and shifts towards drought-resistant landscaping.
The Worst-Case Scenario involves a failure of the strategic refocus to improve core profitability, coinciding with a broader economic slowdown that pressures consumer spending on lawn care. This could lead to a covenant breach or liquidity crunch given the strained balance sheet. The realistic downside is a retest and break below the 52-week low of $52. From the current price of $59, this implies a potential loss of approximately -12%. In a more severe stress scenario where the company's financial instability becomes a primary concern, the stock could fall towards levels implied by its deeply negative book value, potentially resulting in losses of 30-40% or more.
FAQ
The key risks are, in order of severity: 1) Financial Risk: The balance sheet is critically leveraged with a debt-to-equity ratio of -6.66, risking insolvency if cash flow weakens. 2) Operational Risk: Extreme seasonality leads to deep quarterly losses (e.g., -$125M in Q1 2026), and recent trends show deterioration. 3) Market Risk: A high beta of 1.862 means the stock is highly correlated and more volatile than the market, amplifying losses in downturns. 4) Liquidity & Sentiment Risk: Limited analyst coverage (only 3 analysts) reduces visibility and can lead to sharp price moves on news.
The 12-month forecast is highly uncertain, with three distinct scenarios. The Base Case (50% probability) sees the stock trading between $55 and $70 as the turnaround progresses slowly. The Bull Case (20% probability), fueled by a successful refocus and debt reduction, targets $72 to $85. The Bear Case (30% probability), triggered by operational failure and balance sheet stress, could see the stock fall to $42-$52, retesting its 52-week low. The Base Case is most likely, assuming the company muddles through without a major crisis or dramatic recovery.
Based on its Price-to-Sales (PS) ratio of 0.96, SMG appears deeply undervalued relative to its own historical average, which has been as high as 15.76. However, this low multiple is a direct reflection of the market's severe discount for the company's financial distress, negative equity, and volatile earnings. Compared to industry peers, specific data is unavailable, but a sub-1.0 PS typically signals low growth expectations or significant problems. Therefore, the stock is fairly valued for its current high-risk profile—it is cheap for a reason.
SMG is not a good buy for most investors due to its severe financial risks and speculative nature. It could be considered a high-risk, high-reward speculation for investors who believe the strategic refocus will succeed and who can tolerate the potential for significant volatility, as indicated by its beta of 1.86. The stock trades at a deep-value PS ratio of 0.96, but this is counterbalanced by a negative ROE of -40.6% and widening quarterly losses. It is only suitable for a very small portion of a risk-seeking portfolio with a long-term horizon.
SMG is unsuitable for short-term trading due to its high volatility and lack of clear near-term catalysts outside of earnings reports. Given its status as a multi-year turnaround story with significant balance sheet repair needed, it is theoretically a long-term investment. However, the extreme risks mean only investors with a multi-year horizon and high risk tolerance should consider it, and even then, it should be a very small position. The lack of a dividend and earnings visibility further supports a long-term, watchful holding period, with the understanding that the investment could be a total loss if the turnaround fails.